With classical ADC therapies demonstrating sustained clinical success and reshaping the standard of oncology care, eyes are turning towards up-and-coming novel conjugate with non-cytotoxic payloads and novel targeting moieties compared to tried and tested ADCs. 

Don’t miss this session delving into the challenges and opportunities of ISAC and non-cytotoxic ADC development, alongside non-antibody conjugates including PDCs and beyond.